Astec Lifesciences Limited (ASTEC) AI Stock Analysis

Astec Lifesciences Limited

(NSE:ASTEC)

Select Model

Rating:52Neutral

Price Target:INR 552.00▲(1.02% Upside)

Action:reiterated

Date:09/23/26

Strong technical momentum is the primary driver of the score, as the stock shows robust bullish signals. However, this is significantly offset by weak financial performance, characterized by cash burn and unprofitability, and a negative P/E ratio that underscores the company's fundamental challenges.

Positive Factors

Agrochemical product breadthAstec participates across several crop-protection product stages and applications, supplying both active ingredients and intermediates alongside select formulations. This operating base gives the company relevance across insecticide, herbicide, and fungicide demand and supports a durable position in agricultural inputs.

Negative Factors

Sustained large lossesAstec's shift from positive profits in FY22–FY23 to sizable losses through FY26 shows that revenue recovery has not yet translated into economic profitability. Persistent negative operating profit can weaken reinvestment capacity, reduce financial flexibility, and make a durable earnings recovery more difficult.

Astec Lifesciences Limited (ASTEC) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 16.19B
Dividend Yield: ―
Average Volume (3M): 11.04K
Price to Earnings (P/E): -15.3
Beta (1Y): 1.27
Revenue Growth: 16.06%
EPS Growth: 36.97%
Country: India
Employees: 471
Sector: General
Sector Strength: 55
Industry: Agricultural Inputs

Astec Lifesciences Limited Business Overview & Revenue Model

Company Description

Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the co...

Astec Lifesciences Limited Financial Statement Overview

Summary

Revenue recovery and improved leverage are positives, but persistent net losses and deeply negative cash flows indicate significant financial strain. The overall trend is stabilizing but remains weak.

Income Statement

25Negative

Balance Sheet

35Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	4.41B	4.48B	3.81B	4.58B	6.28B	6.77B
Gross Profit	552.59M	419.01M	-685.16M	1.33B	2.27B	2.86B
EBITDA	89.92M	-15.49M	-662.07M	-2.69M	893.14M	1.65B
Net Income	-665.97M	-809.17M	-1.35B	-469.30M	255.65M	898.59M
Balance Sheet
Total Assets	0	9.42B	8.81B	9.75B	9.79B	8.97B
Cash, Cash Equivalents and Short-Term Investments	100.49M	122.51M	8.55M	16.47M	27.54M	33.44M
Total Debt	0	4.49B	5.55B	4.94B	3.41B	2.79B
Total Liabilities	-3.91B	5.51B	6.46B	6.05B	5.60B	5.00B
Stockholders Equity	3.91B	3.91B	2.35B	3.69B	4.19B	3.96B
Cash Flow
Free Cash Flow	-234.96M	-1.18B	-302.20M	-1.25B	-426.03M	-803.74M
Operating Cash Flow	-199.52M	-1.13B	-83.99M	102.21M	746.56M	236.04M
Investing Cash Flow	-73.41M	-49.07M	-152.30M	-1.35B	-1.13B	-1.04B
Financing Cash Flow	297.62M	1.27B	237.33M	1.25B	377.70M	804.77M

Astec Lifesciences Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price546.40

Price Trends

50DMA666.60Negative

100DMA677.57Negative

200DMA665.28Negative

Market Momentum

MACD-26.68Positive

RSI26.21Positive

STOCH5.13Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTEC, the sentiment is Negative. The current price of 546.40 is below the 20-day moving average (MA) of 683.55, below the 50-day MA of 666.60, and below the 200-day MA of 665.28, indicating a bearish trend. The MACD of -26.68 indicates Positive momentum. The RSI at 26.21 is Positive, neither overbought nor oversold. The STOCH value of 5.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ASTEC.

Astec Lifesciences Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ASTEC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:SHARDACROP	79Outperform	INR 59.96B	9.58	―	2.26%	18.52%	49.11%
IN:DHANUKA	73Outperform	INR 43.75B	16.48	―	0.20%	-5.63%	-11.38%
IN:IPL	66Neutral	INR 12.97B	12.05	―	0.67%	17.05%	9.10%
IN:BHARATRAS	63Neutral	INR 15.49B	6.86	―	0.05%	-5.17%	4.24%
IN:INSECTICID	58Neutral	INR 15.10B	11.82	―	0.39%	1.26%	-16.43%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ASTEC	52Neutral	INR 12.18B	-15.28	―	―	16.06%	36.97%

* General Sector Average

Performance Comparison

IN:ASTEC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ASTEC	Astec Lifesciences Limited	546.40	-124.85	-18.60%
IN:BHARATRAS	Bharat Rasayan Limited	931.80	-1752.46	-65.29%
IN:DHANUKA	Dhanuka Agritech Limited	981.50	-322.04	-24.70%
IN:INSECTICID	Insecticides (India) Limited	519.10	-200.11	-27.82%
IN:IPL	India Pesticides Ltd.	112.60	-77.23	-40.68%
IN:SHARDACROP	Sharda Cropchem Ltd.	664.60	-135.86	-16.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 23, 2026

Astec Lifesciences Limited AI Stock Analysis